Carapezzi William R JR 4

4 · PFIZER INC · Filed Feb 25, 2022

Form 4

Period: 2022-02-23

Executive Vice President

Transactions

Exercise/Conversion
Common Stock
2022-02-23$27.34/sh+25,632$700,779→ 82,914 total
Tax Payment
Common Stock
2022-02-23$46.87/sh−4,057$190,152→ 78,857 total
Tax Payment
Common Stock
2022-02-23$51.28/sh−12,687$650,589→ 66,170 total
Exercise/Conversion
Stock Appreciation Rights
2022-02-23−25,632→ 0 total
Exercise: $27.34From: 2022-02-23Exp: 2022-02-23→ Common Stock (25,632 underlying)
Award
Stock Appreciation Rights
2022-02-24+22,823→ 22,823 total
Exercise: $45.96From: 2027-02-24Exp: 2027-02-24→ Common Stock (22,823 underlying)
Award
Stock Appreciation Rights
2022-02-24+20,073→ 20,073 total
Exercise: $45.96From: 2029-02-24Exp: 2029-02-24→ Common Stock (20,073 underlying)

Holdings

Footnotes (6)

[F1]The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).
[F2]The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights.
[F3]The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon).
[F4]Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.
[F5]The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.
[F6]The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant.

Documents

1 file